Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial

PURPOSE: In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, J., Schäfer, N., Schaub, C., Tzaridis, T., Zeyen, T., Schneider, M., Potthoff, A. L., Giordano, F. A., Steinbach, J. P., Zeiner, P. S., Kowalski, T., Sabel, M., Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G., Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J. C., Bullinger, L., Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U., Seidel, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886607/
https://www.ncbi.nlm.nih.gov/pubmed/36609807
http://dx.doi.org/10.1007/s11060-022-04203-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886607/
https://www.ncbi.nlm.nih.gov/pubmed/36609807
http://dx.doi.org/10.1007/s11060-022-04203-4

Ejemplares similares